Emergent BioSolutions reaches deal to offload travel vaccines to Bavarian Nordic for up to $380M

Gaithersburg biotech Emergent BioSolutions Inc. (NYSE: EBS) said Wednesday it has reached an agreement to sell its travel health business to Denmark’s Bavarian Nordic in a deal that could reach as much as $380 million with milestone payments. The sale agreement comes a little more than a month after Emergent initiated an “organizational restructuring plan” to focus on its drugs and vaccines that protect against public health threats, along with its contract development and manufacturing services.